Optiver Holding’s ALX Oncology ALXO Stock Holding History

Optiver Holding’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$54	Hold	27	–	–	﹤0.01%	2257
2025 Q4	$31	Sell	27 -1	-4%	-$2	﹤0.01%	2406
2025 Q3	$51	Buy	+28	New	+$24	﹤0.01%	2617

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Optiver Holding's ALXO Position: Q1 2026 in Review

Optiver Holding held its ALX Oncology (ALXO) position steady in Q1 2026 at 27 shares worth $54. The position accounts for ﹤0.01% of the portfolio, ranked #2257.

Optiver Holding first reported a position in ALXO in Q3 2025 and has held it in 3 quarters since. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

Optiver Holding held 27 shares of ALX Oncology worth $54 as of Q1 2026.
Optiver Holding left its ALX Oncology share count unchanged in Q1 2026.
ALX Oncology made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #2257 holding.
Optiver Holding first reported a position in ALX Oncology in Q3 2025 and has held it in 3 quarters since.
69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.